National Stem Cell, Inc. Closes Private Placement.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- National Stem Cell, Inc., a biotechnology company, today announced the successful completion of a private placement of common stock to new and existing accredited investors. National Stem Cell is looking forward to completing its reverse merger with Azurel (ticker: AZUR) and accelerating its research mission. "We're pleased with the successful closing of our private placement," says Michael Cohen, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of National Stem Cell, Inc. "The offering proceeds will enable us to take the first step towards our goal -- the research and development of breakthrough stem cell therapeutics. Our team now looks forward to completing the announced reverse merger." For more information, please contact Deanna Decker at 212-752-8338 and ddecker@psbpr.com. This press release contains forward-looking statements regarding the Company's financial or business outlook. Such statements are based on management's current beliefs and expectations. There are a number of risks and uncertainties that could cause actual results or events to differ materially from management's current beliefs and expectations. National Stem Cell, Inc. does not undertake any obligation to update forward-looking statements. About National Stem Cell, Inc. National Stem Cell, Inc. (NSCI NSCI No Significant Cost Impact ) is a biotechnology company headquartered in New York dedicated to the advancement of regenerative medicine. Incorporated in 2005, NSCI operates the Sperm Bank of New York as a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. . Through its sponsored research agreement with the Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. School of Medicine's Institute for Cell Engineering (ICE), NSCI is focused on the development of potential stem cell therapies for the treatment of diabetes and cardiac injury. The company also plans to develop a genetically diverse umbilical cord blood umbilical cord blood Transplantation A source of primitive and stem cells that can be used to reconstitute BM destroyed by aplastic anemia or by RT or chemotherapy for CA, lymphoproliferative malignancies. See Bone marrow transplantation, Stem cell therapy. bank to meet the growing need for transplant grade umbilical cord blood stem cells. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion